Balancing the benefits and costs of colony-stimulating factors: A current perspective

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 13, 2003, Pages 10-17

  Lyman, Gary H ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR;

CANCER CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; FEBRILE NEUTROPENIA; HOSPITAL COST; HOSPITALIZATION; HUMAN; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

EID: 0141856613     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00312-9     Document Type: Article

References (38)

1. Lyman GH, Kuderer NM, Djulbegovic B: Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: A meta-analysis. Am J Med 112:406-411, 2002
2. Ozer H, Armitage JO, Bennett CL, et al: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18:3558-3585, 2000
3. Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 332:901-906, 1995
4. Budman DR, Berry DA, Cirrincione CT, et al: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer: The Cancer and Leukemia Group B. J Natl Cancer Inst 90:1205-1211, 1998
5. Kwak LW, Halpern J, Olshen RA, et al: Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 8:963-977, 1990
6. Epelbaum R, Faraggi D, Ben-Arie Y, et al: Survival of diffuse large cell lymphoma: A multivariate analysis including dose intensity variables. Cancer 66:1124-1129, 1990
7. Lepage E, Gisselbrecht C, Haioun C, et al: Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte), Ann Oncol 4:651-656, 1993
8. Lyman GH, Kuderer NM: Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs 62:65-78, 2002 (suppl 1)
9. Crawford J, Ozer H, Stoller R, et al: Reduction in the incidence of chemotherapy-induced febrile neutropenia in patients with small cell lung cancer. N Engl J Med 325:164-170, 1991
10. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-324, 1993
11. de Graaf H, Willemse PHB, Bong SB, et al: Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. Oncology 53:289-294, 1996
12. Pettengell R, Gurney H, Radford JA, et al: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430-1436, 1992
13. Citron ML, Berry MA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 21:1431-1439, 2003
14. Pfreundschuh M, Trumper L, Kloess M, et al: 2-weekly vs 3-weekly CHOP with and without etoposide for patients >60 years of age with aggressive non-Hodgkin's lymphoma (NHL): Results of the completed NHL-B-2 trials of the DSHNHL. Blood 100:774a, 2002 (abstr 3060)
15. Lyman GH, Lyman CG, Sanderson RA, et al: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 85:488-493, 1993
16. American Society of Clinical Oncology: Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 12: 2471-2508, 1994
17. American Society of Clinical Oncology: Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol 14:1957-1960, 1996
18. American Society of Clinical Oncology: 1997 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 15:3288, 1997
19. Lyman GH: A predictive model for neutropenia associated with cancer chemotherapy. Pharmacotherapy 20:104S-111S, 2000
20. Lyman GH, Kuderer N, Greene J, et al: The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 34:1857-1864, 1998
21. Calhoun EA, Chang CH, Welshman EE, et al: A neutropenia-specific quality of life instrument: Rationale for the development of the FACT-N. Proc Am Soc Clin Oncol 21: 375a, 2002 (abstr 1498)
22. Cosler LE, Agboola O, Calhoun EA, et al: An updated risk threshold model for G-CSF prophylaxis use in cancer chemotherapy: incorporation of patient out-of-pocket and indirect costs. International Society for Pharmacoeconomics and Outcomes Research 7th Annual International Meeting, May 19-22, 2002. Arlington, VA. Value Health 5:138, 2002 (abstr PCN12)
23. Fortner B, Solshek B, Tauer KW, et al: Chemotherapy-induced neutropenia (CIN) is associated with lower quality of life in patients with cancer. Ann Oncol 13:174, 2002 (suppl 15) (abstr)
24. Okon TA, Fortner BV, Schwartzberg L, et al: Quality of life (QOL) in patients with grade IV chemotherapy-induced neutropenia (CIN). Proc Am Soc Clin Oncol 21:275b, 2002 (abstr 2920)
25. Glaspy J, Hackett J, Flyer P, et al: Febrile neutropenia is associated with an increase in the incidence, duration, and severity of chemotherapy toxicities. Blood 98:432a, 2001 (abstr 1812)
26. Holmes FA, O'Shaughnessy JA, Vukelja S, et al: Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727-731, 2002
27. Green MD, Koelbl H, Baselga J, et al: A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29-35, 2003
28. Lyman GH, Kuderer NM, Crawford J. Economic impact of pegfilgrastim use based on the risk of febrile neutropenia (FN) in NHL patients treated with CHOP. Proc Am Soc Clin Oncol 22:593, 2003 (abstr 2384)
29. Silber JH, Fridman M, Shpilsky A, et al: Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. J Clin Oncol 16:2435-2444, 1998
30. Moore T, Shiftan TA, Knight CA, et al: A prospective trial assessing a risk model for filgrastim use on chemotherapy (CT) dose intensity (DI) in the adjuvant treatment of stage I-III breast cancer patients (BCP). Proc Am Soc Clin Oncol 20:8b, 2001 (abstr 1778)
31. Savvides P, Terrin N, Erban J, et al: Development and validation of a patient-specific predictive instrument for the need for dose reduction in chemotherapy for breast cancer. A potential decision aid for the use of myeloid growth factors. Supp Care Cancer 11:313-320, 2003
32. Thomas ES, Rivera E, Erder MH, et al: Using first cycle nadir absolute neutrophil count (FCNANC) as a risk factor for neutropenic events: A validation study. Proc Am Soc Clin Oncol 20:37a, 2001 (abstr 144)
33. Intragumtornchai T, Sutheesophon J, Sutcharitchan P, et al: A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 37:351-360, 2000
34. Tompkins KA, Imrie KR: Neutropenic events in patients receiving CHOP chemotherapy for large cell non-Hodgkin's lymphoma: Predicting who is at risk. Blood 98:337a-338a, 2001 (abstr 1427)
35. Lyman GH, Lyman CH, Dale DC, et al: Risk models for the prediction of chemotherapy-induced neutropenia (CIN) and its consequences: A systematic review and classification. Blood 98:413b, 2001 (abstr 5443)
36. Wilson-Royalty M, Lawless G, Palmer C, et al: Predictors for chemotherapy-related severe or febrile neutropenia: A review of the clinical literature. J Oncol Pharm Pract 7:141-147, 2001
37. Lyman GH, Crawford J, Dale DC, et al: Predicting the risk of chemotherapy-induced neutropenia in patients with breast cancer: Rationale for prospective risk model development. Breast Cancer Res Treat 76:S537, 2002 (abstr)
38. Dale DC, Wolff D, Agboola O, et al: Prospective patient registry for the development of risk models of neutropenic complications including febrile neutropenia (FN). Blood 100: 502b, 2002 (abstr 5593)